PriceTargets.com logo

CERo Therapeutics - CERO Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $45.00
  • Forecasted Upside: 129,210.34%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.03 As of 03/19/2026 04:54 PM ET
▲ +0.0018 (5.45%)

This chart shows the closing price for CERO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CERo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CERO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CERO

Analyst Price Target is $45.00
▲ +129,210.34% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for CERo Therapeutics in the last 3 months. The average price target is $45.00, with a high forecast of $60.00 and a low forecast of $30.00. The average price target represents a 129,210.34% upside from the last price of $0.03.

This chart shows the closing price for CERO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 3 polled investment analysts is to reduce stock in CERo Therapeutics. This rating has held steady since October 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
2/17/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/18/2025D. Boral CapitalReiterated RatingBuy ➝ Hold
11/3/2025Maxim GroupDowngradeBuy ➝ Hold
10/30/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00
10/22/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00
10/13/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/23/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00
9/5/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00
8/4/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00
6/23/2025D. Boral CapitalUpgradeHold ➝ Buy$30.00
5/30/2025D. Boral CapitalReiterated RatingBuy ➝ Hold
5/19/2025Maxim GroupInitiated CoverageBuy$60.00
4/22/2025D. Boral CapitalUpgradeStrong-Buy
4/22/2025D. Boral CapitalInitiated CoverageBuy ➝ Buy$220.00 ➝ $220.00
(Data available from 3/19/2021 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2025
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
9/20/2025
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2025
  • 3 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/19/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
CERo Therapeutics logo
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
Read More

Today's Range

Now: $0.03
Low: $0.03
High: $0.04

50 Day Range

MA: $0.04
Low: $0.03
High: $0.05

52 Week Range

Now: $0.03
Low: $0.03
High: $28.40

Volume

206,734 shs

Average Volume

551,446 shs

Market Capitalization

$723.94 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.29

Frequently Asked Questions

What sell-side analysts currently cover shares of CERo Therapeutics?

The following Wall Street analysts have issued stock ratings on CERo Therapeutics in the last year: D. Boral Capital, Maxim Group, and Weiss Ratings.
View the latest analyst ratings for CERO.

What is the current price target for CERo Therapeutics?

0 Wall Street analysts have set twelve-month price targets for CERo Therapeutics in the last year. Their average twelve-month price target is $45.00, suggesting a possible upside of 129,210.3%. Maxim Group has the highest price target set, predicting CERO will reach $60.00 in the next twelve months. D. Boral Capital has the lowest price target set, forecasting a price of $30.00 for CERo Therapeutics in the next year.
View the latest price targets for CERO.

What is the current consensus analyst rating for CERo Therapeutics?

CERo Therapeutics currently has 1 sell rating and 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for CERO.

What other companies compete with CERo Therapeutics?

Other companies that are similar to CERo Therapeutics include Avalon GloboCare, Vaccinex, Enveric Biosciences, Functional Brands and Adial Pharmaceuticals. Learn More about companies similar to CERo Therapeutics.

How do I contact CERo Therapeutics' investor relations team?

CERo Therapeutics' physical mailing address is 2001 MARKET STREET SUITE 3400, PHILADELPHIA PA, 19103. The company's listed phone number is 215-731-9450 and its investor relations email address is [email protected]. The official website for CERo Therapeutics is www.cero.bio. Learn More about contacing CERo Therapeutics investor relations.